NCIMMUNE LEADING EARLY CANCER DETECTION

EarlyCDT®Lung and Autoantibody Technology.

Early in the development of a solid tumour, the body mounts an immune response to certain by-products or proteins from cancer cells (these proteins are known as tumour antigens). As the presence of these proteins become more marked or intense, different types of protein known as autoantibodies (immuno-biomarkers) are produced by the human body in response to the cancer cells. These autoantibodies are directed against the tumour antigens and are produced in sufficient quantities that they can be measured in an individual’s blood using a simple blood test.

An individual’s blood sample is then processed and a procedure known as an assay is carried out which measures the autoantibodies or in the sample.

This technology has made the detection of a cancer possible up to four years earlier than current diagnostic tests such as a chest x-ray or spiral CT (Computed Tomography)1.

Oncimmune has completed extensive studies of more than 120,000 samples since 2007 to validate and prove the assay technology and develop it into a reliable laboratory test. Since then over 150,000 commercial tests have also been run in the US laboratory.

Oncimmune has been able to produce proteins (tumour antigens) in the laboratory which match the cancer proteins causing the body to generate the cancer specific autoantibodies. This concept can be applied for use in the early detection of any solid tumour cancer.

1. Zhong L, Coe SP, Stromberg AJ, et al.: Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 1:513–519, 2006.

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept